Navigation Links
UC Davis researchers develop new drug delivery system for bladder cancer using nanoparticles
Date:10/25/2012

(SACRAMENTO, Calif.) -- A team of UC Davis scientists has shown in experimental mouse models that a new drug delivery system allows for administration of three times the maximum tolerated dose of a standard drug therapy for advanced bladder cancer, leading to more effective cancer control without increasing toxicity.

The delivery system consists of specially designed nanoparticles that home in on tumor cells while carrying the anti-cancer drug paclitaxel. The same delivery system also was successfully used to carry a dye that lights up on imaging studies, making it potentially useful for diagnostic purposes. The findings are published today in the journal Nanomedicine.

"We have developed a novel, multifunctional nanotherapeutics platform that can selectively and efficiently deliver both diagnostic and therapeutic agents to bladder tumors," said Chong-Xian Pan, principal investigator of the study and associate professor of hematology and oncology at UC Davis. "Our results support its potential to be used for both diagnostic and therapeutic applications for advanced bladder cancer."

Cancer of the bladder usually develops in the cells of the inner lining of the bladder. Survival rates are high if the disease is caught early, but it remains difficult to treat in advanced stages ― when the tumor has grown outside of the bladder or metastasized to distant sites. It is the fourth most common cancer in men; it occurs less frequently in women.

Paclitaxel is a drug used to treat advanced bladder cancer and other cancers, but it is associated with serious safety concerns. It can be toxic to bone marrow, leading to reduced levels of red and white blood cells, putting patients at risk of infection. In addition, because the drug is not readily soluble in blood, it is typically dissolved in castor oil, which has caused severe ― and sometimes fatal ― allergic reactions.

The drug delivery system used in thi
'/>"/>

Contact: Dorsey Griffith
dorsey.griffith@ucdmc.ucdavis.edu
916-734-9118
University of California - Davis Health System
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. UC Davis study finds that above-normal weight alone does not increase the short-term risk of death
2. UC Davis scientists find new role for P53 genetic mutation -- initiation of prostate cancer
3. Far from random, evolution follows a predictable genetic pattern, Princeton researchers find
4. USF researchers identify gene mutation linked to old age hearing loss
5. USDA scientists collaborate with global researchers to advance the mapping of the barley genome
6. Danish researchers release ground-breaking knowledge about calcium pumps in cells
7. CU-Boulder researchers uncover new target for cancer research
8. Columbia researchers report novel approach for single molecule electronic DNA sequencing
9. Researchers develop new stamping process to pattern biomolecules at high resolution
10. Mount Sinai researchers awarded Provocative Questions grant from National Cancer Institute
11. RUB researchers clarify catalysis mechanism of cell growth protein Ras
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/11/2015)... and Markets ( http://www.researchandmarkets.com/research/3p32qm/access_control ) has announced ... Product, Application & By Geography - Global Forecast & ... This report predicts that the access control ... with an estimated CAGR of 10.6%. The ... as contact cards & readers, contactless cards & readers, ...
(Date:3/10/2015)... NEW YORK , March 10, 2015  Continuing ... and the Unexpected, Hammacher Schlemmer introduces The Eye ... user,s identity before granting access to secure websites or ... trusted to verify travelers at international borders, the device ... 240 distinctive pattern points of the iris, converting them ...
(Date:3/10/2015)... Utah , March 10, 2015   Tute ... interpretation, has been selected by next-generation sequencing company ... of whole exome and targeted gene panel interpretation. ... provider, has adopted the most current technologies to support ... genetic research. The company offers two types of exome ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3
... will gather in Maputo, Mozambique, 21-24 October, for the ... Science (ICSU)the first time an ICSU GA will be ... scientists from around the world will come together at ... can contribute to solving some of the most pressing ...
... green may be heart healthy if the green ... at Penn State who conducted the first study ... "We investigated mechanisms of action to explain the ... K. Gebauer, recent Penn State Ph.D. recipient, currently ...
... Boulder, CO, USA Counting on wetlands restoration projects ... is likely to be a "losing battle" that provides ... for their future, says a researcher from Western Carolina ... Gulf of Mexico this fall, the media has been ...
Cached Biology News:Global science community to gather in Mozambique 2Researchers study how pistachios may improve heart health 2Wetlands restoration not a panacea for Louisiana coast 2Wetlands restoration not a panacea for Louisiana coast 3
(Date:3/25/2015)... Francisco, CA (PRWEB) March 25, 2015 ... Support for Novel Mechanism of Action in Neuromuscular ... 25, 2015 – Cytokinetics, Incorporated (Nasdaq: CYTK) announced ... fast skeletal muscle troponin activator tirasemtiv in the ... a Phase IIa “Evidence of Effect” or hypothesis-generating ...
(Date:3/25/2015)... and the HAGUE, Netherlands , March ... of LES Stimulation therapy for chronic gastro-esophageal reflux disease ... Surgery [ Surgery . 2015; 157(3):556-567 ], ... minimally-invasive therapy. The study included 25 ... 11 years and taking prescribed daily proton pump inhibitor ...
(Date:3/25/2015)... COLLEGE PARK, Md. , March 25, 2015 ... of two years of intense research by scientists ... University of Maryland and represent a breakthrough in ... an assistant professor in the Department of Animal & ... faculty research assistant in ANSC, successfully produced genome-edited ...
(Date:3/25/2015)... , March 25, 2015  CASI Pharmaceuticals, Inc. ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a commercial focus on China ... 2 trial of its target therapy drug candidate ENMD-2076 ... of Chinese Academy of Medical Sciences in ...
Breaking Biology Technology:Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 2EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 3University of Maryland Researchers Successfully Produce Genome-edited Pigs Using Revolutionary Technology 2CASI Pharmaceuticals Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China 2CASI Pharmaceuticals Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China 3CASI Pharmaceuticals Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China 4CASI Pharmaceuticals Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China 5
... Informed Medical Communications (IMC), a leading provider of ... announced the appointment of Kerry Crawford to the ... this critical role, Kerry will lead operations and ... relationship management systems. This key addition is ...
... sweeteners partner to produce world,s first probiotic-enhanced ... baking aisleINDIANAPOLIS, March 3 Ganeden ... the patented probiotic strain GanedenBC30, today announced ... , an Indianapolis-based leading innovator of health ...
... Inc.,(OTC Bulletin Board: CLXS), a leading developer of ... launch of the world,s first,CTSA Experts Platform drawing ... more than 60,000 life science researchers. The platform ... of the Clinical Translational Science,Awards (CTSA,s) from the ...
Cached Biology Technology:Informed Medical Communications Appoints New Senior Manager, Strategic Operations 2Ganeden Biotech and Heartland Sweeteners to Produce Probiotic Sweetener 2Ganeden Biotech and Heartland Sweeteners to Produce Probiotic Sweetener 3Collexis Connects the NIH Clinical and Translational Science Award Programs with CTSA Expert Platform 2Collexis Connects the NIH Clinical and Translational Science Award Programs with CTSA Expert Platform 3
McCoy's 5A Medium. Without Tryptose or Phosphate Broth. Contains Sodium Bicarbonate....
... This complete kit contains ... separations from a total of ... cells, and includes the StemSep ... necessary reagents and buffers for ...
... Methylation Kit uses a simplified procedure and ... analysis. The kit is based on the ... cytosine and sodium bisulfite where cytosine is ... Kits innovative in-column desulphonation reaction eliminates several ...
... to RFC1 Immunogen Recombinant protein corresponding ... C expressed in E. coli. Reactivity / ... Not yet tested in other species. This antibody ... Background Information Replication factor C is a ...
Biology Products: